Skip to main navigation Skip to search Skip to main content

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC

  • Masayuki Shirasawa
  • , Tatsuya Yoshida
  • , Takaji Matsutani
  • , Yuki Takeyasu
  • , Naoko Goto
  • , Shigehiro Yagishita
  • , Shigehisa Kitano
  • , Hiroaki Kuroda
  • , Toyoaki Hida
  • , Takayasu Kurata
  • , Yuichiro Ohe
  • National Cancer Center Japan
  • Kitasato University
  • Repertoire Genesis Inc.
  • Maruho Co., Ltd.
  • Kansai Medical University
  • Japanese Foundation for Cancer Research
  • Aichi Cancer Center Hospital and Research Institute

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, conducted from November 2019 to May 2021 at three institutions in Japan, evaluated the diversity of TCR repertoire (DE50) in PD-1 + CD8 + T-cells and CD8 + T-cell phenotypes in peripheral blood before and after CRT. Forty patients treated with CRT were included. The diversity and usage of TCR beta variable chains (TRBV) and 14 junctional chains (TRBJ) were significantly and positively correlated before and after CRT. Regarding the DE50, the progression-free survival (PFS) of patients with DE50High before CRT was significantly greater than that of those with DE50Low (NR vs. NR months, HR 0.17, p = 0.01). The diversity of TCR repertoire might more accurately predict the efficacy of CRT followed by durvalumab therapy.

Original languageEnglish
Article number17
Journalnpj Precision Oncology
Volume9
Issue number1
DOIs
StatePublished - Dec 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC'. Together they form a unique fingerprint.

Cite this